Increasing Availability of Emulsion Adjuvants via Synthetic Biology

通过合成生物学提高乳液助剂的可用性

• 批准号: 10691630
• 负责人: CHASE KEMPINSKI
• 金额: $ 299.63万
• 依托单位: ENEPRET, INC.
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-08-30 至 2025-08-29
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10691630
• 关键词: Adjuvant; Animals; Blood; COVID-19 vaccine; Cyclic GMP; Emulsions; Immunology procedure; In Vitro; Influenza A virus; MF59; Marketing; Oils; Pharmacology and Toxicology; Process; Production; Property; Squalene; Testing; Tissues; Vaccines; Water; Yeasts; base; influenza virus vaccine; novel; preclinical study; seasonal influenza; synthetic biology; vaccine evaluation; vaccine immunogenicity

Squalene-based oil-in-water emulsions, such as MF59, have been shown to demonstrate adjuvant activity in a variety of vaccine settings, including seasonal influenza vaccine. The awardee seeks to develop a mimic of MF59 using squalene that has been sustainably synthesized by yeast cultures. This adjuvant will be tested in preclinical studies and advanced toward large production capacity.

已经证明，基于小孢子的水中油乳液（例如MF59）在包括季节性流感疫苗在内的多种疫苗环境中表现出辅助活性。获奖者旨在使用酵母培养物可持续合成的小孢子来开发MF59的模仿。该佐剂将在临床前研究中进行测试，并朝着大生产能力迈进。